Sudeep Pharma debuted strongly on D-Street with nearly 24% listing gains, aligning with grey market expectations. The Rs 895-crore IPO saw robust demand, subscribing 93.71 times. Strong institutional interest, solid financials, high margins, and leadership in specialised ingredients underpin investor confidence as the stock begins trading on the secondary market.